What is Thermalin?
Thermalin is at the forefront of diabetes care innovation, developing novel insulin formulations designed to address critical unmet needs. Their preclinical pipeline includes ultra-rapid-acting insulin, insulin requiring no refrigeration, glucose-responsive insulin, and a once-weekly insulin patch. These molecular designs are based on exclusive licensing from Dr. Michael Weiss at Case Western Reserve University School of Medicine. Thermalin's research and development have been bolstered by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the US NIH, and support from the JDRF and the Leona M. and Harry B. Helmsley Charitable Trust. The company's focus on improving patient quality of life through advanced insulin technology positions it as a key player in the diabetes therapeutics market.
How much funding has Thermalin raised?
Thermalin has raised a total of $14.3M across 6 funding rounds:
Other Financing Round
$2.2M
Series A
$2.9M
Unspecified
$2.5M
Series B
$5.9M
Debt
$350K
Debt
$429K
Other Financing Round (2010): $2.2M with participation from JumpStart
Series A (2011): $2.9M led by JumpStart
Unspecified (2012): $2.5M, investors not publicly disclosed
Series B (2014): $5.9M featuring Undisclosed
Debt (2020): $350K backed by PPP
Debt (2021): $429K with participation from PPP
Key Investors in Thermalin
JumpStart
JumpStart is a venture development organization that provides capital, services, and connections to foster entrepreneurial growth and innovation.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Thermalin?
With substantial enterprise-level backing and a recent strategic investment, Thermalin is poised for significant advancement in its development pipeline. The company's focus on a diverse range of insulin innovations, from ultra-rapid-acting to long-acting formulations, suggests a strategy aimed at capturing a broad segment of the diabetes market. Future endeavors will likely concentrate on progressing these preclinical programs through clinical trials, seeking regulatory approvals, and potentially forging strategic partnerships for commercialization. The company's commitment to addressing the challenges of diabetes management through molecular innovation indicates a strong growth trajectory.
See full Thermalin company page
